Beruflich Dokumente
Kultur Dokumente
1001
DIABETICMedicine
DOI: 10.1111/j.1464-5491.2009.02866.x
Review Article
Peripheral arterial disease in diabetesa review
E. B. Jude, I. Eleftheriadou* and N. Tentolouris*
Tameside General Hospital, Ashton-Under-Lyne, UK and *Athens University Medical School, Athens, Greece
Accepted 23 September 2009
SFMV
Doc usage interne
Ne pas diffuser
Abstract
Diabetic patients are at high risk for peripheral arterial disease (PAD) characterized by symptoms of intermittent
claudication or critical limb ischaemia. Given the inconsistencies of clinical findings in the diagnosis of PAD in the
diabetic patient, measurement of ankle-brachial pressure index (ABI) has emerged as the relatively simple, non-invasive
and inexpensive diagnostic tool of choice. An ABI < 0.9 is not only diagnostic of PAD even in the asymptomatic patient,
but is also an independent marker of increased morbidity and mortality from cardiovascular diseases. With better
understanding of the process of atherosclerosis, avenues for treatment have increased. Modification of lifestyle and
effective management of the established risk factors such as smoking, dyslipidaemia, hyperglycaemia and hypertension
retard the progression of the disease and reduce cardiovascular events in these patients. Newer risk factors such as
insulin resistance, hyperfibrinogenaemia, hyperhomocysteinaemia and low-grade inflammation have been identified,
but the advantages of modifying them in patients with PAD are yet to be proven. Therapeutic angiogenesis, on the
other hand, represents a promising therapeutic adjunct in the management of PAD in these patients. Outcomes after
revascularization procedures, such as percutaneous transluminal angioplasty and surgical bypasses in diabetic
patients, are poorer, with increased perioperative morbidity and mortality compared with that in non-diabetic
patients. Amputation rates are higher due to the distal nature of the disease. Efforts towards increasing
awareness and intensive treatment of the risk factors will help to reduce morbidity and mortality in diabetic patients
with PAD.
Diabet. Med. 27, 414 (2010)
Keywords ankle-brachial pressure index, diabetes, peripheral arterial disease, risk factors, treatment
Abbreviations ABI, ankle-brachial pressure index; bFGF, basic fibroblast growth factor; cAMP, cyclic adenosine-3,5monophosphate; CRP, C-reactive protein; DM, diabetes mellitus; HGF, hepatocyte growth factor; HTN, hypertension;
LDL, low-density lipoprotein; MI, myocardial infarction; NGF, nerve growth factor; NO, nitric oxide; PAD, peripheral
arterial disease; PAI, plasminogen activator inhibitor; PCTA, percutaneous transluminal balloon angioplasty; SBP,
systolic blood pressure; T1DM, Type 1 diabetes mellitus; T2DM, Type 2 diabetes mellitus; TcPO2, transcutaneous
partial pressure of oxygen; UKPDS, United Kingdom Prospective Diabetes Study; VEGF, vascular endothelial growth
factor; vWF, von Willebrand factor
Introduction
Peripheral arterial disease (PAD) is a group of disorders
characterized by narrowing or occlusion of the arteries
resulting in gradual reduction of blood supply to the limbs.
Patients with PAD may be asymptomatic or may develop
symptoms of intermittent claudication or symptoms of critical
limb ischaemia, characterized by pain in the peripheries at rest,
DIABETICMedicine
Incidence
Review article
NA
586
2002
UK
11
ABI, ankle-brachial pressure index; IC, intermittent claudication; NA, not available.
NA
5209
IC
General population
(26% with diabetes mellitus)
Type 1 diabetes mellitus
Framingham
4
1985
17.3%
38.0%
23.5%
8.7%
33.0%
3% in age < 60 years
20% in age 75 years
173
1084
864
213
48
642
ABI < 0.9
IC or pulse deficit
ABI < 0.9
ABI < 0.9
ABI < 0.9
IC, pulse deficit,
non-invasive testing
Type 1 and Type 2 diabetes mellitus
Type 1 and Type 2 diabetes mellitus
Type 2 diabetes mellitus
Type 1 diabetes mellitus
Type 1 and Type 2 diabetes mellitus
General population
Hoorn study
Australia
UK
UK
UK
North America
6
8
9
9
7
10
1995
1984
1992
1992
1999
1985
1073
Pulse deficit
Type 1 and Type 2 diabetes mellitus
Population
Years
19451969
USA, Minnesota
5
Country
Incidence
References
Table 1 Epidemiological data for peripheral arterial disease in patients with and without diabetes mellitus
Prevalence
Diagnostic criterion
Number of
patients
Prevalence
8.0%
Epidemiology
DIABETICMedicine
Amputation rate
Mortality
Review article
DIABETICMedicine
Risk factor
1,4,5,9,15,17,28
4,5,10
1,5,11,17,18,21,28
17,28
4,15,17
4,11,15,17,19
9,11,15,17,18,20,21
22
23
9,15,21
11,24
1,15
25
9,11,18
26
26
27
Increasing age
Male gender
Duration of diabetes mellitus
Degree of hyperglycaemia
Smoking
Hypertension
Dyslipidaemia
Increased serum lipoprotein (a) levels
Reduced serum apolipoprotein (a) levels
Obesity, central body fat distribution
Insulin resistance
Increased serum fibrinogen levels
Hyperhomocysteinaemia
Microalbuminuria
Increased levels of von Willebrand factor
Increased levels of thrombinantithrombin complexes
Increased levels of intercellular adhesion molecules
1, 2
2
1, 2
2
2
1, 2
1, 2
1, 2
2
2
1, 2
2
Non-diabetics
1, 2
2
2
2
Clinical presentation
The majority of diabetic patients with PAD are asymptomatic
(up to 75%) when ABI < 0.9 is the criterion for the diagnosis. The
Diagnosis of PAD
A history of intermittent claudication or absence of peripheral
pulses on palpation is unreliable for detection of PAD. The
dorsalis pedis pulse is absent congenitally in about 1015% of the
population. However, a history of claudication, presence of
bruits proximally and findings of chronic ischaemia in the
peripheries such as cold feet, pallor on limb elevation and
dependent rubor, trophic skin changes and distal gangrene are all
DIABETICMedicine
Treatment
The aims in the management of the diabetic patient with PAD are
to improve symptoms and to prevent cardiovascular morbidity
and mortality. Treatment of PAD can be considered in three
stages: lifestyle and risk factor modifications, drug therapy and
vascular interventions.
Lifestyle modifications
Table 3 The role of ankle-brachial pressure index (ABI) for the diagnosis of peripheral arterial disease (PAD) in patients with diabetes mellitus
Advantages
References
Disadvantages
References
Simple
1,28
28,40
Non-invasive
1,28
Reproducible
1,28
1,28
12
38
Review article
DIABETICMedicine
FIGURE 1 Proposed protocol for the diagnosis of peripheral arterial disease (PAD) in patients with and without diabetes mellitus. Reprinted with
permission from N Engl J Med 2001; 344: 16081621. ABI, ankle-brachial index; TBI, toe-brachial index.
DIABETICMedicine
Drug therapy
Antiplatelet agents
10
Review article
DIABETICMedicine
FIGURE 2 Proposed protocol for the management of peripheral arterial disease (PAD) in patients with diabetes mellitus (DM). AE, adverse effects; VEGF,
vascular endothelial growth factor; bFGF, basic fibroblast growth factor; HGF, hepatocyte growth factor; NGF, nerve growth factor; PCTA, percutaneous
transluminal balloon angioplasty; BG, bypass grafting.
into thigh and calf muscles in patients with severe limb ischaemia
resulted in improvement in clinical outcomes [57]. However,
only a few patients with DM were included in these studies and
we must wait to gain confidence in the efficacy of these treatments
in patients with DM. HGF and NGF promote neovascularization
in experimental DM [57] and experience in humans is limited.
Human bone-marrow cells contain stem cells that have the
potential for differentiation into a variety of tissues, including
endothelium. Transplantation of autologous bone-marrow stem
cells in 10 patients with severe PAD into the common femoral
artery and the thigh and calf muscles resulted in clinical
improvement and increase in ABI. In another study, autologous
peripheral blood stem cells in 62 patients with severe PAD were
11
DIABETICMedicine
Revascularization procedures
Outcomes
12
Summary
Patients with DM are prone to develop PAD. PAD begins
earlier, progresses more rapidly and is more commonly
asymptomatic in DM. Distal arterial involvement of the tibial
and peroneal arteries is the predominant pattern. Lifestyle
modifications are of benefit. Drug therapy is advised in patients
who do not respond to lifestyle modification. Antiplatelet
therapy can retard the onset and progression of PAD and reduce
cardiovascular events in diabetic patients. Therapeutic
angiogenesis represents a promising therapeutic adjunct in the
management of PAD and further research is needed. The results
of revascularization procedures for proximal lesions are similar
to those in non-diabetic patients, but results in distal bypasses
are poor in the long term. Amputation rates after
revascularization are much higher in diabetic than in nondiabetic patients. Mortality in general and perioperative
mortality are also high in diabetic patients. Early, aggressive
management of the risk factors and timely referral for
revascularization might improve outcome in patients with PAD.
Competing interests
Nothing to declare.
References
1 American Diabetes Association. Peripheral arterial disease in people
with diabetes. Diabetes Care 2003; 26: 33333341.
2 Jude EB. Intermittent claudication in the patient with diabetes. Br J
Diabetes Vasc Dis 2004; 4: 238242.
3 Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial
disease in diabetic and nondiabetic patients: a comparison of
severity and outcome. Diabetes Care 2001; 24: 14331437.
4 Kannel WB, McGee DL. Update on some epidemiologic features of
intermittent claudication: the Framingham Study. J Am Geriatr Soc
1985; 33: 1318.
5 Melton LJ III, Macken KM, Palumbo PJ, Elveback LR. Incidence and
prevalence of clinical peripheral vascular disease in a populationbased cohort of diabetic patients. Diabetes Care 1980; 3: 650654.
6 Beks PJ, Mackaay AJ, de Neeling JN, de Vries H, Bouter LM, Heine
RJ. Peripheral arterial disease in relation to glycaemic level in an
elderly Caucasian population: the Hoorn study. Diabetologia 1995;
38: 8696.
7 Elhadd T, Robb R, Jung R, Stonebridge P, Belch J. Pilot study of
prevalence of asymptomatic peripheral arterial occlusive disease in
patients with diabetes attending a hospital clinic. Pract Diabetes Int
1999; 16: 163166.
8 Welborn TA, Knuiman M, McCann V, Stanton K, Constable IJ.
Clinical macrovascular disease in Caucasoid diabetic subjects: logistic regression analysis of risk variables. Diabetologia 1984; 27:
568573.
Review article
DIABETICMedicine
27 Jude EB, Douglas JT, Anderson SG, Young MJ, Boulton AJ. Circulating cellular adhesion molecules ICAM-1, VCAM-1, P- and Eselectin in the prediction of cardiovascular disease in diabetes
mellitus. Eur J Intern Med 2002; 13: 185189.
28 Marso SP, Hiatt WR. Peripheral arterial disease in patients with
diabetes. J Am Coll Cardiol 2006; 47: 921929.
29 Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis:
epidemiology, pathophysiology, and management. JAMA 2002;
287: 25702581.
30 Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH
et al. Diabetes mellitus enhances vascular matrix metalloproteinase
activity: role of oxidative stress. Circ Res 2001; 88: 12911298.
31 Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+)
homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol
2001; 280: H1480H1489.
32 Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet
dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476
1485.
33 Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes
Complications 2001; 15: 4454.
34 Hirsch AT, Hiatt WR. PAD awareness, risk, and treatment: new
resources for survivalthe USA PARTNERS program. Vasc Med
2001; 6: 912.
35 Dyet JF, Nicholson AA, Ettles DF. Vascular imaging and intervention in peripheral arteries in the diabetic patient. Diabetes Metab Res Rev 2000; 16 (Suppl. 1): S16S22.
36 Moulik PK, Mtonga R, Gill GV. Amputation and mortality in newonset diabetic foot ulcers stratified by etiology. Diabetes Care 2003;
26: 491494.
37 Dolan NC, Liu K, Criqui MH, Greenland P, Guralnik JM, Chan C
et al. Peripheral artery disease, diabetes, and reduced lower
extremity functioning. Diabetes Care 2002; 25: 113120.
38 Carser DG. Do we need to reappraise our method of interpreting
the ankle brachial pressure index? J Wound Care 2001; 10: 59
62.
39 Costacou T, Huskey ND, Edmundowicz D, Stolk R, Orchard TJ.
Lower-extremity arterial calcification as a correlate of coronary
artery calcification. Metabolism 2006; 55: 16891696.
40 Aboyans V, Ho E, Denenberg JO, Ho LA, Natarajan L, Criqui MH.
The association between elevated ankle systolic pressures and
peripheral occlusive arterial disease in diabetic and nondiabetic
subjects. J Vasc Surg 2008; 48: 11971203.
41 Tsai JC, Chan P, Wang CH, Jeng C, Hsieh MH, Kao PF et al. The
effects of exercise training on walking function and perception of
health status in elderly patients with peripheral arterial occlusive
disease. J Intern Med 2002; 252: 448455.
42 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year
follow-up of intensive glucose control in type 2 diabetes. N Engl J
Med 2008; 359: 15771589.
43 Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L.
Impact of peripheral arterial disease in patients with diabetesresults from PROactive (PROactive 11). Atherosclerosis 2009;
202: 272281.
44 Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG,
Thorgeirsson G. Cholesterol lowering with simvastatin improves
prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).
Diabetes Care 1997; 20: 614620.
45 Heart Protection Study Collaborative Group. MRC BHF Heart
Protection Study of cholesterol lowering with simvastatin in 20,536
high-risk individuals: a randomised placebo-controlled trial. Lancet
2002; 360: 722.
46 Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA,
Neil HA, Livingstone SJ et al. Primary prevention of
cardiovascular disease with atorvastatin in type 2 diabetes in the
13
DIABETICMedicine
47
48
49
50
51
52
14
Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685
696.
Heart Outcomes Prevention Evaluation Study Investigators. Effects
of ramipril on cardiovascular and microvascular outcomes in people
with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention Evaluation Study
Investigators. Lancet 2000; 355: 253259.
Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR.
Intensive blood pressure control reduces the risk of cardiovascular
events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003; 107: 753756.
Radack K, Deck C. Beta-adrenergic blocker therapy does not
worsen intermittent claudication in subjects with peripheral arterial
disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151: 17691776.
Antiplatelet Trialists Collaboration. Collaborative overview of
randomised trials of antiplatelet therapyI: prevention of death,
myocardial infarction, and stroke by prolonged antiplatelet therapy
in various categories of patients. Antiplatelet Trialists Collaboration. BMJ 1994; 308: 81106.
Antiplatelet Trialists Collaboration. Collaborative overview of
randomised trials of antiplatelet therapyII: maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet
Trialists Collaboration. BMJ 1994; 308: 159168.
Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of
platelet function delays progression of peripheral occlusive arterial
disease. A prospective double-blind arteriographically controlled
trial. Lancet 1985; 1: 415419.